Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Tech Trader Only

(Technical Analysis + Trades by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis

2026-04-23	BUY
Summary: We're going long on BSX right now after the sharp +9% earnings reaction and follow-through buying that signals a potential capitulation low and healthy reset.[[1]](https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q1-2026/) The stock cratered from over $100 last year to the low $60s amid earlier misses and pressure, with our prior long attempts in the $70s getting stopped out as it ground lower. This latest print was different: Q1 beat on revenue and EPS, but management prudently slashed full-year guidance to 6.5-8% organic growth and $3.34-3.41 EPS. The street is treating this as a positive "reset" that removes unrealistic expectations and sets up easier comps into 2027.[[2]](https://www.investing.com/news/stock-market-news/boston-scientific-cuts-2026-profit-forecast-trims-revenue-growth-view-4628989) Volume surged on the 4/22 move (over 40M shares), and it held gains to close near $66 on 4/23 with another solid day. That's the kind of institutional sponsorship we want after months of distribution. Analyst consensus remains Moderate Buy with an average target near $94 (over 40% upside), even after several firms trimmed PTs to the $70-100 range post-earnings. Long-term, BSX has strong positioning in cardiovascular, endoscopy, and emerging launches that should drive acceleration once the current headwinds in EP, WATCHMAN, and Urology stabilize.[[3]](https://www.marketbeat.com/stocks/NYSE/BSX/forecast/) We're not chasing a parabolic move or ignoring the downtrendâ€”risk is real and a retest of the $62 area is possible. But with the reset catalyst absorbed positively, high relative volume, and our last trade over a month ago, this setup has the conviction for a 7+ day hold targeting continuation toward $72-75 initially. If momentum fades or it loses $63.50, we'll exit quickly. Cash has been the right call during the whipsaw period, but the current risk/reward favors being long here with real money.
2026-04-22	CASH
Summary: ...
2026-04-21	CASH
Summary: ...
2026-04-20	CASH
Summary: ...
2026-04-17	CASH
Summary: ...
2026-04-16	CASH
Summary: ...
2026-04-15	CASH
Summary: ...
2026-04-14	CASH
Summary: ...
2026-04-13	CASH
Summary: ...
2026-04-10	CASH
Summary: ...
2026-04-09	CASH
Summary: ...
2026-04-08	CASH
Summary: ...
2026-04-07	CASH
Summary: Staying CASH on BSX as it's in a clear downtrend from over $100 to $62 with repeated gap-down selloffs on weak 2026 guidance and legal overhangs, plus our string of losing long entries showing no reversal yet as of the April 7 close at 61.82 ahead of Q1 earnings....
2026-04-06	CASH
Summary: BSX remains in a clear downtrend after the Feb earnings crash and March breakdown to the 62 area, with every recent long attempt resulting in quick losses, so cash is the safest move until a real base forms. ...
2026-04-02	CASH
Summary: ...
2026-04-01	CASH
Summary: ...
2026-03-31	CASH
Summary: ...
2026-03-30	CASH
Summary: ...
2026-03-27	SOLD
Summary: ...
2026-03-26	BUY
Summary: ...
2026-03-25	CASH
Summary: ...
2026-03-24	CASH
Summary: ...
2026-03-23	CASH
Summary: ...
2026-03-20	CASH
Summary: ...
2026-03-19	SOLD
Summary: ...
2026-03-18	HOLD LONG
Summary: We're holding our long from yesterday at $71.2 as BSX posted another green close at 71.42, keeping the short-term uptrend intact without meaningful selling pressure. ...
2026-03-17	BUY
Summary: Although we stayed in cash yesterday due to the continued downtrend and repeated failed bounces, today's strong follow-through to 71.18 on the third straight up day shifts the picture enough to go long now. ...
2026-03-16	CASH
Summary: BSX remains in a clear downtrend with repeated failed bounces, so we're staying in cash after the recent losing long trades. ...
2026-03-13	CASH
Summary: Staying in cash as BSX persists in a downtrend with price below key EMAs, negative MACD, and unresolved issues like recalls and litigation from recent exit, despite oversold signals and slight bounce....
2026-03-12	SOLD
Summary: Exiting long on BSX at 68.83 as persistent downtrend breaks below lower BB with negative MACD despite oversold RSI, compounded by Class I recall, litigation, and lowered analyst targets overriding March 28 catalyst potential....
2026-03-11	HOLD LONG
Summary: Holding long on BSX despite further dip to 69.17, as deeply oversold RSI 28 with positive MACD histogram, below lower BB signaling potential reversal, supported by recent analyst buy ratings averaging $104 target, $4B buyback, bullish options activity, and upcoming March 28 clinical data catalyst overriding downtrend....
2026-03-10	HOLD LONG
Summary: Holding long on BSX at 69.93 despite dip, as oversold RSI 30, positive MACD histogram persists, near BB lower with upcoming March 28 clinical data catalyst, overriding litigation noise amid analyst growth optimism....
2026-03-09	BUY
Summary: Recommending long on BSX at 71.98 due to oversold RSI 33, positive MACD histogram signaling reversal, price bouncing from 69.52 low near lower Bollinger Band, better entry than recent 72.99 with new March 28 investor event catalyst overriding prior downtrend and no-reversal exit reasons as technicals now show momentum shift....
2026-03-06	SOLD
Summary: Exit long on BSX as price breaks below entry amid persistent downtrend with no immediate reversal signals, despite oversold conditions and positive MACD histogram, to avoid further losses given trade history of failed bounces....
2026-03-05	BUY
Summary: Recommending long on BSX at 72.39 due to oversold RSI 32 near lower Bollinger Band, positive MACD histogram signaling potential reversal, much better entry price than recent 76.22 with new $5B buyback overriding persistent fraud concerns as price has capitulated further without new negatives....
2026-03-04	CASH
Summary: Staying in cash as BSX persists in a downtrend with price below EMA/SMA, negative MACD, and no reversal signals after recent exit, despite oversold RSI near BB lower band at a lower entry price, but fraud probe and weak guidance outweigh any bounce potential without new bullish catalysts....
2026-03-03	SOLD
Summary: Exit long as price drops below entry amid ongoing downtrend, negative MACD despite crossover, and persistent fraud investigation concerns overriding Penumbra acquisition optimism....
2026-03-02	BUY
Summary: Recommending long on BSX at 76.43 due to stabilizing price after capitulation, improving MACD crossover, new bullish acquisition of Penumbra overriding ongoing investigation concerns, with better entry than recent 77.64 exit and changed circumstances from 2/11 dip/exit as price has bounced with positive merger catalyst....
2026-02-27	CASH
Summary: Staying in cash as BSX shows tentative recovery but remains in a downtrend below key EMAs with ongoing fraud investigations, a new stent recall posing risks, countered somewhat by potential Penumbra acquisition, yet overall caution prevails after recent exit amid high uncertainty....
2026-02-26	CASH
Summary: Staying in cash as BSX churns sideways in downtrend below EMAs amid unresolved fraud probes, no volume reversal despite oversold RSI, echoing failed bounces without new catalysts overriding prior exit reasons....
2026-02-25	CASH
Summary: Staying in cash as BSX remains in a downtrend with oversold RSI but no clear reversal, ongoing shareholder misleading investigation, and bearish market reaction to cautious 2026 guidance, mirroring the recent exit at similar price levels without material positive changes....
2026-02-24	CASH
Summary: Ongoing securities fraud probes (multiple firms as recent as yesterday) and persistent downtrend below EMAs outweigh oversold RSI (~28-40) and Moderate Buy consensus PTs ($108-125 avg, 45%+ upside)....
2026-02-23	CASH
Summary: Staying in cash as BSX remains in a downtrend with ongoing securities fraud investigations overriding oversold signals and minor bullish news like unusual calls and sector deals, especially after recent exit due to similar concerns....
2026-02-20	CASH
Summary: Staying in cash as unresolved securities fraud probes and persistent downtrend outweigh oversold RSI (~30-48) and Strong Buy consensus PTs ($108-125, 40%+ upside)....
2026-02-19	CASH
Summary: Staying in cash as BSX lingers in downtrend below EMAs/SMAs amid unresolved fraud probes and no bullish reversal despite oversold RSI and 40%+ upside to $108-125 PTs....
2026-02-18	CASH
Summary: Staying in cash as BSX remains in downtrend with ongoing fraud investigation and no strong reversal signals post-earnings miss, despite oversold indicators....
2026-02-17	CASH
Summary: Staying in cash as BSX remains in a confirmed downtrend with price below key EMAs/SMAs, ongoing securities fraud investigation overriding oversold RSI/STO signals, and history of failed bounces, avoiding re-entry without resolution to negatives or stronger bottom confirmation....
2026-02-13	CASH
Summary: Staying in cash as BSX remains in a downtrend post-earnings miss and amid ongoing securities fraud investigations, with no clear reversal signals despite oversold technicals, avoiding quick re-entry after recent exit without new positive catalysts....
2026-02-12	CASH
Summary: Staying in cash as BSX remains in a sharp downtrend post-earnings miss and ongoing securities fraud investigation, with oversold indicators but no confirmed reversal amid high risk of further downside to supports around $71....
2026-02-11	SOLD
Summary: Exit long position as price dips further below entry amid ongoing downtrend and new securities fraud investigation, overriding oversold signals with no clear reversal catalysts....
2026-02-10	BUY
Summary: Recommending long entry at 74.5 on oversold RSI/STO with volume capitulation signaling potential bottom, better price than recent 77.64 exit, and analysts maintaining buy ratings despite guidance deceleration, as the downtrend may reverse with no further negative catalysts....
2026-02-09	CASH
Summary: Staying in cash as BSX continues its confirmed downtrend post-bearish 2026 guidance, with price below EMA/SMA, oversold RSI but no strong reversal signals amid high-volume capitulation and repeated failed bounces in history....
2026-02-06	CASH
Summary: Staying in cash as BSX remains in a strong downtrend post-bearish 2026 guidance with price below EMA/SMA, oversold indicators suggesting potential bounce but no confirmed reversal amid high volume drop and broken supports, avoiding quick re-entry after yesterday's exit without new positive catalysts....
2026-02-05	SOLD
Summary: Exit long on bearish 2026 guidance miss with decelerating growth and weak EP segment, triggering 18% plunge to oversold levels amid confirmed downtrend and high-volume capitulation....
2026-02-04	HOLD LONG
Summary: Q4 beat (EPS $0.80 vs $0.78 est, rev $5.29B vs $5.28B) with FY25 +20% growth; 2026 guide 10-11% rev/ $3.43-3.49 EPS solid, EP miss caused -15% dip to ~$78â€”oversold buy.[[1]](https://news.bostonscientific.com/2026-02-04-Boston-Scientific-announces-results-for-fourth-quarter-and-full-year-2025)[[2]](https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q4-2025)[[3]](https://www.zacks.com/stock/news/2828591/boston-scientific-bsx-beats-q4-earnings-and-revenue-estimates)...
2026-02-03	HOLD LONG
Summary: Oversold RSI ~23 pre-Feb4 earnings beat potential (15%+ rev growth est) + 30%+ upside to $125 PTs outweigh dip digestion....
2026-02-02	HOLD LONG
Summary: TD Cowen reiterates Buy today amid Strong Buy consensus PT $125+ (30%+ upside), framing pre-earnings dip as oversold entry with transformative acquisitions....
2026-01-29	HOLD LONG
Summary: Consensus Strong Buy avg PT $125 (35% upside) amid Penumbra neurovascular synergies and Feb4 Q4 earnings beat potential frame $92.70 dip as entry....
2026-01-28	HOLD LONG
Summary: Consensus Strong Buy PT $125+ (33% upside from $93s)[[1]](https://www.marketwatch.com/investing/stock/bsx/analystestimates?gaa_at=eafs&gaa_n=AWEtsqcNMbuIQrfPZ5AcF9BNsIjTrj7DuuUb-1_9wmLr910Ql5PlpxHdVIey&gaa_sig=EQhVZ0RwPcqTZUHH-nvX0VK6r1EWxNFevptu80RD8YkwvE3udE5yfUZD-dROIz4PJg6conddcsMFE4p-ez9-_w%3D%3D&gaa_ts=697a774f)[[2]](https://www.zacks.com/stock/research/BSX/price-target-stock-forecast) amid Penumbra neurovascular bolt-on synergies and Q4 earnings beat potential frame dip as entry.[[3]](http://business.times-online.com/times-online/article/marketminute-2026-1-28-boston-scientific-to-acquire-penumbra-for-145-billion-in-massive-medtech-consolidation)...
2026-01-27	HOLD LONG
Summary: Consensus Strong Buy PT $125+ (33% upside from $93s)[[1]](https://www.marketwatch.com/investing/stock/bsx/analystestimates?gaa_at=eafs&gaa_n=AWEtsqe_8lJRi2_FROPcEUwYmegxyMVIH8_usq074RvXLdy7Ng3j_BuYbqsZ&gaa_sig=snx9nQOXCnHY74Fb-mChW4HEjeRbUqHX5J22fa5vUPl5AQTqYhKds_EMkrylrfLoDsXbAkLrm2e-AwFzVo2TPQ%3D%3D&gaa_ts=697925a7)[[2]](https://www.marketbeat.com/stocks/NYSE/BSX/forecast) amid institutional adds, oversold RSI rebound, and Feb4 earnings beat potential outweigh dip....
2026-01-26	HOLD LONG
Summary: Consensus Buy PT $125+ (33% upside from $93s)[[1]](https://www.marketwatch.com/investing/stock/bsx/analystestimates?gaa_at=eafs&gaa_n=AWEtsqdMQR88pQ6vAfInydZz034ANMGBYsBXNRAOtl-QHHBcPRCi0zmD5o4W&gaa_sig=_bIkvEEJWkVj-uI3vvEN289oZB7zR7SZfrSPt43ISzKQFz8qZGhMgopiDCwnVrhvBiPeUSHdHJUjWJ1CJXUmqw%3D%3D&gaa_ts=6977ff82)[[2]](https://www.zacks.com/stock/research/BSX/price-target-stock-forecast) amid Penumbra $14.5B neurovascular bolt-on and institutional adds frame dip as entry ahead of Q4 earnings beat.<grok:render type="render_inline_citation">...
2026-01-23	HOLD LONG
Summary: Zacks upgrades Q4 EPS outlook to $0.81 beat potential, Vanguard +0.5% record stake amid Penumbra neurovascular tailwinds frame $89 oversold rebound....
2026-01-22	HOLD LONG
Summary: Stifel reiterates Buy post-Penumbra digestion, institutional adds (Vanguard +0.5%) frame $89 dip as oversold entry ahead of Feb4 earnings....
2026-01-21	HOLD LONG
Summary: Stifel's praise for Penumbra acquisition expands neurovascular footprint with minimal overlap, framing post-deal dip as entry with 25%+ upside to consensus PTs....
2026-01-20	HOLD LONG
Summary: Stifel/ Truist praise Penumbra $14.5B neurovascular bolt-on as transformative, dip to $95 exhausts as JP conf tailwinds build to Q4 earnings....
2026-01-16	HOLD LONG
Summary: Stifel praises $14.5B Penumbra acquisition boosting neurovascular/heart portfolio, Truist Buy reiterated amid initial dip digestion for 25%+ upside....
2026-01-15	HOLD LONG
Summary: Morgan Stanley sees BSX undervalued after $14.5B Penumbra acquisition bolstering heart devices, dip to $95.72 buy opp with JP conf tailwinds....
2026-01-14	HOLD LONG
Summary: Eastern Bank +9.2% to 293k shares, First Horizon new $570k, GRIMES +188% post-Valencia/JP conf outweigh dip, 25%+ upside primed....
2026-01-13	HOLD LONG
Summary: Valencia acquisition expands urology (eCoin FDA-approved ITNS, 3hrs ago) + JP Morgan conf today (CEO Mahoney) outweigh 2% dip to $95.72, 25% upside intact....
2026-01-12	HOLD LONG
Summary: Valencia Tech acquisition (9hrs ago) bolsters bladder franchise, UBS $140/RBC $130 PTs + JP Morgan conf tomorrow ignite 25%+ upside....
2026-01-09	HOLD LONG
Summary: JP Morgan Healthcare conf Jan13 nears with CEO Mahoney spotlight, consensus Buy PT $125+ holds as $98 base firms up pre-earnings....
2026-01-08	HOLD LONG
Summary: Earnings preview flags low double-digit Q4 growth beat potential, RAINBOW AXIOS study update (TipRanks 1day) boosts pipeline as $97.79 holds firm....
2026-01-07	HOLD LONG
Summary: Consensus Buy from 24 analysts (20 Buy/2 Hold) amid Gladstone +39.5% stake, +2.42% pop to $97.79 beats market, JP Morgan conf looms....
2026-01-06	HOLD LONG
Summary: Evercore ISI Outperform $112 (9hrs ago) with consensus PT $125+ amid JP Morgan conf Jan13/Q4 call Feb4 outweigh mixed flows for 25%+ upside....
2026-01-05	HOLD LONG
Summary: Synergy Asset +479k shares (3x stake) and JP Morgan Healthcare conf Jan13 announcement outweigh Calamos trim, consensus Buy eyes 25%+ upside....
2026-01-02	HOLD LONG
Summary: Ninety One UK +4.2% to $524M stake, Generali +7.7%, Merit +4.6% flows dominate as JP Morgan conf/Q4 call loom with 25%+ upside....
2025-12-31	HOLD LONG
Summary: Stifel $125 Buy reiterated (Jan2), Oppenheimer $125 Buy, Raymond James +3.1% stake amid $93.99 close signal rebound continuation....
2025-12-30	HOLD LONG
Summary: Stifel Buy $125 (32% upside, 18hrs ago), consensus "Buy" from 24 analysts (Defense World 2days) amid Norden +442% stake surge....
2025-12-29	BUY
Summary: Consensus "Buy" from 24 analysts (Defense World 15hrs ago), Seeking Alpha $109 target (14% upside, 2days), Norden +442% stake outweigh dips....
2025-12-26	CASH
Summary: Staying in cash as BSX remains in a confirmed downtrend with price below both EMA and SMA, no recent volume capitulation for a long entry, repeated past losing trades on stalled bounces, and being a biotech stock precludes shorting despite bearish technicals....
2025-12-24	CASH
Summary: Staying in cash as BSX remains in a downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, repeated failed bounces in trade history, and biotech nature prohibits shorting despite bearish technicals....
2025-12-23	CASH
Summary: Staying in cash as the current downtrend with EMA below SMA, price below both, and both moving downward precludes new long entries without recent volume capitulation, while shorting is avoided for this biotech stock prone to sudden positive news....
2025-12-22	CASH
Summary: The trend remains down with EMA below SMA and price below both without recent volume capitulation, while past similar long entries led to repeated losses amid weakening momentum....
2025-12-19	CASH
Summary: The stock remains in a downtrend with EMA below SMA and price below both, lacking volume capitulation or strong reversal signals, while recent trade history highlights repeated long entry failures amid weakening momentum....
2025-12-18	CASH
Summary: Staying in cash as BSX is in a clear downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting is avoided due to its biotech nature prone to sudden positive news spikes....
2025-12-17	CASH
Summary: In a confirmed downtrend without recent volume capitulation, avoiding new long entries to prevent repeating past losses from stalled bounces, and refraining from shorting this biotech stock due to high risk of sudden positive news spikes....
2025-12-16	CASH
Summary: Staying in cash as BSX remains in a downtrend with EMA below SMA, price below both, no flagged volume capitulation for a safe long entry, and repeated past losses from similar stalled bounce attempts amid weakening momentum....
2025-12-15	CASH
Summary: Staying in cash as BSX remains in a confirmed downtrend with EMA below SMA, price below both, no recent volume capitulation for a long entry, and shorting is avoided for this biotech stock amid repeated failed bounces in trade history....
2025-12-11	CASH
Summary: Staying in cash due to confirmed downtrend without volume capitulation, avoiding shorts on biotech stock like BSX prone to sudden news spikes, and no high-confidence long setup amid repeated failed recoveries in trade history....
2025-12-10	CASH
Summary: Staying in cash due to confirmed downtrend without volume capitulation, BSX's history of failed long entries on stalled bounces, overbought RSI not signaling reversal, and no imminent catalysts for upside conviction....
2025-12-09	CASH
Summary: Technicals indicate a downtrend with price below EMA and SMA, no volume capitulation for long entry, and shorting biotech like BSX risks massive spikes from news, so stay in cash awaiting clearer setup. No flagged volume capitulation in the past two months means we can't justify buying this dip in a downtrend, even though RSI at 31.51 suggests oversold conditions and price nears support around 92.70 from earlier this year....
2025-12-08	CASH
Summary: Staying in cash as the trend remains unclear with price below both EMA and SMA amid recent high-volume selling without capitulation signals, mirroring past failed long entries on stalled bounces, and no high-conviction setup for shorting this medical device stock given its potential for sudden positive catalysts....
2025-12-05	CASH
Summary: Staying in cash due to unclear trend with price below flattening EMA and SMA, no recent volume capitulation for a long entry in potential downtrend, and repeated past failed bounce trades indicating low win rate on similar setups near support. Only the FDA approval seems materially impactful, potentially supporting upside, but technicals must come first and currently don't align for entry. No volume capitulation flagged recently, and while near support at 97.45 (with prior bounces), history shows similar dips led to quick breakdowns, like the November pullback from 104 to 96 without sustained recovery. MACD is negative at -0.4564, RSI at 41.39 indicates oversold but not extreme, and Slow STO suggests weakening momentum....
2025-12-04	CASH
Summary: Staying in cash due to unclear trend with price below both EMA and SMA, no volume capitulation for long entry in potential downtrend, repeated past losses on stalled recoveries, and no immediate catalysts or strong technical buy signals for a multi-week hold....
2025-12-03	CASH
Summary: Staying in cash due to unclear trend with EMA slightly above SMA but price below both, no volume capitulation, and recent trade history of repeated long losses on stalled bounces, avoiding entry until clearer uptrend or strong bottom signal....
2025-12-01	CASH
Summary: Staying in cash as the trend remains unclear with EMA and SMA tightly bound, frequent price crossings over the past month, and no volume capitulation to support a long entry despite a recent bounce from support near 97.45....
2025-11-28	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA tightly rangebound and moving sideways, price frequently crossing them without clear direction, mirroring past losing trades from stalled bounces and whipsaws in similar setups....
2025-11-26	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA tightly bound, frequent crossings in the past month, sideways movement without upward momentum, and history of failed bounces leading to losses....
2025-11-25	CASH
Summary: Staying in cash due to unclear trend with recent EMA/SMA cross, tight ranging averages, and multiple price crossings of moving averages in the past month, avoiding new entries per technical guidelines despite the recent bounce, while learning from repeated past losses on stalled recoveries....
2025-11-24	CASH
Summary: Staying in cash due to unclear trend with price below both EMA and SMA, no fresh volume capitulation for entry, and repeated past long trade failures on stalled bounces amid weakening momentum....
2025-11-21	SOLD
Summary: Exiting the existing long position as price has declined steadily below key moving averages on high volume, testing support near 95-99 without recovery signals, mirroring repeated past losing trades on stalled bounces despite positive fundamentals and no near-term catalysts....
2025-11-20	HOLD LONG
Summary: Holding existing long position as minimum hold period not met, price near key support 95-99 without breaking capitulation low of 94.89, positive historical earnings reactions, and no immediate catalysts, despite downtrend and recent losses mirroring past failed recoveries....
2025-11-19	HOLD LONG
Summary: Holding existing long position as minimum hold period not met despite recent price drop below EMA/SMA amid weakening momentum, with no immediate earnings or catalysts, potential support near 99-95, and positive historical earnings reactions suggesting recovery potential....
2025-11-18	HOLD LONG
Summary: Holding existing long position as technicals show price above rising SMA with positive MACD, no resistance hit for exit, and minimum hold period not met amid potential support near 99 without capitulation....
2025-11-17	HOLD LONG
Summary: Holding long position as technicals remain supportive with price above rising EMA, positive MACD, and no major breakdowns, targeting resistance near 108 amid recent volatility and past stalled bounces....
2025-11-14	HOLD LONG
Summary: Maintaining long position as technicals remain supportive with price above rising EMA/SMA, positive MACD, and no breakdowns or catalysts, targeting resistance near 108 despite minor pullback and past stalled bounces....
2025-11-13	HOLD LONG
Summary: Maintaining long position as technicals show continued uptrend with price above EMA/SMA, positive MACD momentum, and no immediate catalysts or breakdowns, targeting resistance near 108 for multi-week hold despite past stalled bounces....
2025-11-12	BUY
Summary: Entering long on confirmed uptrend with price above EMA and SMA, positive MACD crossover, RSI not overbought, and strong post-earnings momentum from October, targeting multi-week hold towards prior highs near 108 despite recent trade losses from stalled bounces....
2025-11-11	CASH
Summary: Staying in cash as the trend remains unclear with recent EMA/SMA crossover, multiple price crossings of moving averages in the past month without fresh volume capitulation, and repeated historical losses on premature long entries amid choppy momentum, while no downtrend setup allows shorting this biotech stock. Volume has been moderate without extreme spikes, and the prior "BOT" capitulation on 10/2/2025 is already played out with the bounce to SMA, so it can't justify a new long in what was a downtrend. Technicals like RSI at 59.97 indicate neutral momentum, MACD at 0.34 showing early bullish crossover but weak, and Stochastic overbought at 53.35, suggesting potential for whipsaw rather than sustained move. Support at $92.70 and rising trendline around $92.89 provide downside buffers, but resistance at $103.86 (falling trendline) and prior high $108.94 cap upside, keeping it rangebound....
2025-11-10	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA, both tightly rangebound and moving sideways without clear direction, avoiding new entries per technical guidelines after recent losing longs, with no immediate catalysts or volume capitulation to justify a position....
2025-11-06	CASH
Summary: Staying in cash as the trend remains unclear with EMA below SMA, price below both in a sideways-to-down move without new volume capitulation, and recent trade history shows repeated failed long entries post-similar setups. This setup advises against new positions, especially after the string of losing longs in the trade history, where entries after the 10/2/2025 BOT capitulation at $94.89 failed to sustain upward momentum, leading to exits on stalled bounces and persistent downtrends....
2025-11-05	CASH
Summary: Staying in cash as the trend is unclear with price crossing EMA twice in the past month amid a downtrend without fresh capitulation, recent losses on longs highlight risks, and BSX's biotech nature prohibits shorts despite bearish technicals like declining averages and neutral RSI....
2025-11-04	CASH
Summary: Staying in cash as the clear downtrend persists without new volume capitulation for a long entry, recent capitulation is invalidated for reuse after bouncing to SMA, and shorting is prohibited due to the biotech sector and capitulation within the past two months. The October 2 volume capitulation at $94.89 flagged as "BOT" provided a prior entry point, but that signal is no longer valid for new longs since the price has already bounced to the SMA and the bounce stalled, leading to the recent exit on October 9. No fresh capitulation has occurred, and the stock remains below key moving averages with bearish MACD crossover and RSI in neutral territory, suggesting continued weakness....
2025-11-03	CASH
Summary: Staying in cash as the current downtrend prohibits new long entries without fresh volume capitulation, while shorting is barred for this biotech stock especially after recent capitulation, with no high-conviction setups amid post-earnings pullback and repeated prior losses. Shorting is explicitly avoided for biotech stocks like BSX due to risks of sudden positive news, and the October 2 capitulation within the past two months further disqualifies it. Recent trade history reveals multiple failed long attempts post-capitulation, with quick stalls and losses, suggesting caution to avoid repeating mistakes like entering on weak bounces....
2025-10-31	CASH
Summary: Staying in cash as the trend remains unclear with EMA below SMA and no confirmed uptrend, despite positive post-earnings momentum, to avoid repeating past losses from premature entries in uncertain conditions....
2025-10-30	CASH
Summary: Staying in cash as the trend remains unclear with EMA below SMA, price fluctuating between them without clear direction, and recent post-capitulation long attempts resulted in losses, suggesting caution until a stronger uptrend or new bottom signal emerges....
2025-10-29	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price between them, frequent crossings in the past month without volume capitulation, and recent post-earnings pullback mirroring prior losing trades after failed bounces....
2025-10-28	CASH
Summary: Staying in cash as the trend remains unclear with EMA below SMA, price fluctuating around key levels post-earnings without a clear uptrend or new capitulation signal, and recent trade history indicates caution to avoid repeating failed long entries amid choppy action....
2025-10-27	CASH
Summary: Trend remains unclear with EMA below SMA despite recent post-earnings bounce, no new volume capitulation for long entry in potential downtrend, and history of losses on failed recoveries warrant staying in cash for better setup. Over the past month, EMA and SMA have not crossed frequently but have trended sideways to downward without clear upward momentum, fitting the unclear trend definition that prohibits new entries. Price has crossed the averages a couple times during the dip and recovery, but without volume capitulation at recent lows, this doesn't qualify for a long in a downtrend scenario. MACD is positive at 0.542 above its signal line (-0.2987), suggesting some building momentum, but RSI at 58.84 is neutral, and Slow STO K/D at 82/81 indicates overbought conditions that could lead to pullbacks, as seen in prior trades where we exited on stalled bounces....
2025-10-24	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price barely above both but both not trending upward, no new volume capitulation for entry in potential downtrend, post-earnings pullback without confirmed reversal, and recent trade history of losses on premature longs....
2025-10-23	CASH
Summary: Staying in cash as the trend remains unclear with EMA below SMA despite price above both, recent earnings reaction already priced in without sustained momentum, and past trades show repeated losses from premature entries post-bounces. ...
2025-10-22	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA despite price above both, no fresh volume capitulation for entry, potential doji star top on earnings day, and recent trade history shows repeated losses on similar long setups without sustained recovery....
2025-10-21	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA and price between them, no new volume capitulation for long entry, repeated failed bounces in history leading to losses, and earnings tomorrow on 10/22/2025 which do not meet hold-through criteria amid potential volatility....
2025-10-20	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA and price between them, upcoming earnings on 10/22/2025 within 2 days prohibiting entry, no fresh volume capitulation for long setup in downtrend, repeated past losses on similar premature long entries after bounces, and BSX's biotech nature ruling out shorts....
2025-10-17	CASH
Summary: Staying in cash as trend remains unclear with EMA below SMA but price above EMA, recent bounce lacks conviction without sustained momentum, and upcoming earnings on 10/22/2025 prevent new entry given minimum hold period and historical volatility criteria not met for holding through....
2025-10-16	CASH
Summary: Downtrend persists with price below EMA and SMA, recent post-capitulation bounces have failed leading to losses, and upcoming earnings on 10/22/2025 prevent a new long entry that meets minimum hold period without holding through....
2025-10-15	CASH
Summary: Staying in cash due to confirmed downtrend with EMA below SMA and price below both, recent volume capitulation already used without sustained recovery, inability to hold 10-14 days before 10/22/2025 earnings, and repeated losses on similar long setups in trade history....
2025-10-14	CASH
Summary: Staying in cash due to persistent downtrend with EMA below SMA and price below both, recent capitulation signal potentially invalidated by new lows below 94.89 without sustained 5-bar break, upcoming earnings on 10/22/2025 not meeting criteria to hold through, and repeated prior long trade losses indicating poor risk/reward for new entry....
2025-10-13	CASH
Summary: Staying in cash as BSX remains in a confirmed downtrend with price below both EMA and SMA, recent break below the 10/2 capitulation low at $94.89 signaling potential invalidation of prior bottom, no new volume capitulation for re-entry, and upcoming earnings on 10/22/2025 adding risk without meeting hold-through criteria....
2025-10-10	CASH
Summary: Staying in cash due to persistent downtrend, recent long trade losses on similar capitulation setups with win rate below 50%, and upcoming earnings on 10/22/2025 requiring exit before full hold period, despite price above 10/2/2025 BOT low at $94.89 offering a potential dip buy opportunity....
2025-10-09	SOLD
Summary: Exiting the long position as the post-capitulation bounce has stalled with price below entry in a persistent downtrend, no strong recovery signals, and upcoming earnings on 10/22/2025 warrant caution to avoid potential volatility....
2025-10-08	HOLD LONG
Summary: Holding the long position as the BOT volume capitulation at $94.89 on 10/2/2025 remains valid with current price at $96.4 above that low and no sustained breach below for 5 bars, supported by BSX's strong fundamentals in medical devices like recent product approvals and steady revenue growth, though monitoring downtrend with EMA below SMA and price below both for potential weakening momentum....
2025-10-07	HOLD LONG
Summary: Holding the long position as the "BOT" volume capitulation at $94.89 on 10/2/2025 remains valid with price above that low despite ongoing downtrend pressure, supported by BSX's solid fundamentals in medical devices and potential upside from upcoming catalysts, though monitoring for sustained breach below capitulation low to invalidate....
2025-10-06	HOLD LONG
Summary: Holding the long position as the volume capitulation "BOT" signal from 10/2/2025 at $94.89 remains valid with price still above that low in a downtrend, supported by BSX's strong fundamentals and potential for recovery ahead of 10/22/2025 earnings, despite current technical weakness....
2025-10-03	BUY
Summary: Entering long on high conviction volume capitulation "BOT" flagged on 10/2/2025 at $94.89 low, with today's 10/3/2025 close at $97.47 above that level in a downtrend, offering a strong bottom signal for potential multi-week recovery despite recent losses, planning to hold at least 10-14 days but exit before 10/22/2025 earnings....
2025-10-02	CASH
Summary: Staying in cash due to confirmed downtrend with price below both EMA and SMA, recent volume capitulation on today's bar but invalidated by historical pattern of failed bounces after similar signals leading to repeated losses, and low win rate on comparable long setups in the past 6 months....
2025-10-01	CASH
Summary: The stock is in a confirmed downtrend with EMA below SMA and price below both, recent volume capitulation on 9/17 has been invalidated by new lows without a fresh flag, prohibiting long entries in this setup, while shorting biotech like BSX is avoided due to high upside risk from news, with no compelling catalysts to override technical weakness....
2025-09-30	CASH
Summary: Staying in cash as the clear downtrend persists without a new volume capitulation signal for entry, recent long attempts resulted in losses mirroring this setup, and shorting is prohibited for this biotech stock due to sudden news risk....
2025-09-29	CASH
Summary: Staying in cash as BSX is in a clear downtrend with EMA below SMA and price below both, no valid new volume capitulation for long entry, and shorting is prohibited for this biotech stock due to risk of sudden positive news....
2025-09-26	CASH
Summary: Staying in cash after recent exit as the downtrend persists with EMA below SMA and price below both, invalidated volume capitulation, no high-confidence setup for long or short, and BSX's biotech nature prohibits shorting despite bearish technicals....
2025-09-25	SOLD
Summary: Exiting the long position as price has dipped below the 9/17 capitulation low without strong rebound, now in a confirmed downtrend with EMA below SMA and price below both amid recent high-volume selling pressure, mirroring prior losing trades exited on weakened momentum....
2025-09-24	HOLD LONG
Summary: Holding the long position as the 9/17 volume capitulation at $97.47 low remains valid without five consecutive closes below it, with price rebounding from oversold RSI near 29 amid BSX's robust medical device innovations and no imminent negative news....
2025-09-23	HOLD LONG
Summary: Holding the long position as the volume capitulation from 9/17 remains valid without 5 consecutive closes below 97.47, despite recent dips, with oversold RSI at 28 signaling potential rebound amid BSX's strong medical device pipeline and no major negative catalysts....
2025-09-22	HOLD LONG
Summary: Holding the long position as the volume capitulation setup from 9/17 at $98.5 remains valid without 5 consecutive bars closing below the 97.47 low, with current oversold RSI at 25 suggesting potential rebound toward $104-107 resistance amid BSX's solid medical device fundamentals and no immediate catalysts....
2025-09-19	HOLD LONG
Summary: Holding the long position as the volume capitulation setup from 9/17 at $98.5 remains valid without 5 consecutive bars sustaining below the 97.47 low, despite short-term price weakness to 97.68 amid downtrend signals, targeting a multi-week recovery to $104-107 resistance supported by BSX's strong fundamentals in medical devices and no immediate catalysts....
2025-09-18	HOLD LONG
Summary: Holding the long position entered on volume capitulation at $98.5, as it's only 1 day in with no invalidation of the setup, price near oversold lows around $98 without sustained breakdown, targeting recovery to $104-107 resistance over multi-week horizon amid positive BSX fundamentals like recent acquisitions and no immediate catalysts....
2025-09-17	BUY
Summary: Entering long on volume capitulation in downtrend at oversold levels near $98, with better entry price than recent exit, targeting multi-week recovery towards $104-107 resistance amid positive fundamentals and no immediate catalysts....
2025-09-16	CASH
Summary: Staying in cash due to unclear trend with EMA and SMA tightly bound and price below both after a sharp high-volume selloff, no volume capitulation, recent losing longs, and no immediate catalysts outweighing the technical weakness....
2025-09-15	CASH
Summary: Staying in cash as the trend is unclear with price below both EMA and SMA after a high-volume selloff, mirroring prior losing trades, and no volume capitulation or strong catalysts to justify entry....
2025-09-12	CASH
Summary: Staying in cash as the trend is unclear with price below both EMA and SMA after recent high-volume selloff mirroring prior losing trades, no volume capitulation or catalysts to justify entry so soon after 9/10 exit at $105.23 amid weakening momentum and biotech risks....
2025-09-11	CASH
Summary: Trend remains unclear with price below both EMA and SMA following high-volume selloff, no volume capitulation or strong reversal signals, and recent exit from long position on 9/10/2025; staying in cash to avoid poor entry and await clearer uptrend confirmation....
2025-09-10	SOLD
Summary: Exiting the long position as price has dropped below both EMA and SMA on a high-volume selloff, mirroring the prior losing trade exit on 8/13/2025 when trend weakened without recovery signals....
2025-09-09	HOLD LONG
Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive MACD momentum, no immediate catalysts, and supportive medtech sector trends including recent FDA approvals and acquisition integrations. Volume has been steady without capitulation signals, and technical indicators like MACD (0.9263 line above signal 0.6434) and RSI (62.46) indicate sustained bullish momentum without overbought conditions. Support levels at $101.56 and rising trendlines provide a safety net, while resistance near $109-110 suggests potential for further upside if broken....
2025-09-08	HOLD LONG
Summary: Holding the long position as the uptrend persists with price above EMA and SMA, positive MACD, no immediate catalysts, and supportive medtech sector momentum including recent positive clinical data....
2025-09-05	HOLD LONG
Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive MACD momentum, no breakdowns or upcoming catalysts, and supportive medtech sector trends including recent acquisitions....
2025-09-04	HOLD LONG
Summary: Holding the long position as the uptrend persists with price above EMA and SMA, positive momentum from recent highs, supportive medtech sector trends, and no breakdowns or upcoming catalysts....
2025-09-03	HOLD LONG
Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive momentum from recent highs, no breakdowns, and supportive medtech sector trends, with next earnings around October 22, 2025....
2025-09-02	HOLD LONG
Summary: Holding the long position as the uptrend persists with price above EMA and SMA, no breakdowns, supported by positive momentum and medtech sector strength, with next earnings expected around October 22, 2025....
2025-08-29	HOLD LONG
Summary: Holding the long position as the uptrend remains confirmed with price above both EMA and SMA, no breakdowns or immediate catalysts, and supported by positive momentum, strong fundamentals in medtech growth, and recent bullish news on acquisitions and FDA approvals....
2025-08-28	HOLD LONG
Summary: Holding the long position as the uptrend is confirmed with price above both EMA and SMA, no trend breakdowns or immediate catalysts, and positive momentum supported by strong fundamentals and recent bullish news....
2025-08-27	HOLD LONG
Summary: Holding the long position as the uptrend remains confirmed with price above both EMA and SMA, positive momentum targeting resistance at 107-108, and no immediate catalysts or trend breakdowns. Volume is moderate at 3.1M on the latest bar, not indicating capitulation, but the uptrend lacks signs of exhaustion, with RSI at 57.6 (neutral, not overbought) and MACD line (0.44) above signal (0.15) showing bullish divergence. Bollinger Bands are expanding slightly (upper 107.29, lower 101.54), suggesting potential for continued upside without immediate squeeze, and Slow STO (85.5%K, 68.8%D) is high but not extreme, supporting momentum....
2025-08-26	HOLD LONG
Summary: Holding the long position as the uptrend is confirmed with price above both EMA and SMA, no unclear trend signals, and aiming for resistance near 107-108 amid positive momentum and no immediate catalysts....
2025-08-25	HOLD LONG
Summary: Holding the long position as the uptrend remains confirmed with price above both EMA and SMA, no unclear trend signals or volume capitulation, and targeting resistance near 107-108 over the next few weeks without immediate catalysts or earnings risks. Technical indicators support continuation: RSI at 55.09 is neutral, avoiding overbought territory; MACD at 0.2533 with signal at 0.0209 shows positive momentum; Slow STO K at 71.80 and D at 52.98 indicate building strength without exhaustion. Bollinger Bands are narrowing (upper $107.43, lower $101.50), suggesting a potential squeeze breakout upward, consistent with historical patterns where BSX consolidated before resuming climbs, like the rally from $94 in March 2025 to $107 in July....
2025-08-22	HOLD LONG
Summary: Holding the long position as the uptrend is confirmed with price above both EMA and SMA, no unclear trend signals or volume capitulation, and aiming for resistance near 107-108 over the coming weeks without immediate catalysts or earnings risks....
2025-08-21	HOLD LONG
Summary: Holding the long position as the uptrend remains confirmed with price above both EMA and SMA, recent dip appears as a buyable pullback without breaking key supports, no volume capitulation or unclear trend signals, and targeting resistance near 107-108 over multi-week horizon....
2025-08-20	BUY
Summary: Entering long on confirmed uptrend with price above both EMA and SMA after recent breakout from consolidation, supported by positive momentum and no immediate catalysts, targeting multi-week hold towards resistance near 107-108. This follows a period of consolidation around 102-104, and today's strong green candle on decent volume suggests a breakout, reminiscent of similar patterns earlier in 2025 like the January rally where price surged after testing supports....
2025-08-19	CASH
Summary: Staying in cash as the trend remains unclear with price between tightly bound EMA and SMA without a clear uptrend or volume capitulation to justify a new long entry after the recent exit....
2025-08-18	CASH
Summary: Trend remains unclear with EMA slightly above SMA but price below both, frequent tight ranging in the past month without volume capitulation, and recent exit from long position on 8/13/2025 advises caution against re-entry without stronger signals....
2025-08-15	CASH
Summary: Trend is unclear due to multiple EMA/SMA crossings in the past month and price below both averages, warranting staying in cash to avoid low-confidence entries after recent loss....
2025-08-14	CASH
Summary: Staying in cash as the trend remains unclear with price between EMA and SMA after recent exit, no volume capitulation, and avoiding re-entry higher post-loss for better opportunities ahead....
2025-08-13	SOLD
Summary: Exiting the long position as the trend has become unclear with price below both EMA and SMA, recent pullback testing lower supports without clear recovery signals, and no upcoming catalysts to justify holding amid weakening momentum. Volume has been moderate without capitulation flags, and indicators like RSI at 43.15 (neutral but leaning oversold), MACD crossing negative (-0.3081), and Slow STO suggesting fading momentum support caution. ...
2025-08-12	HOLD LONG
Summary: Holding the long position as the uptrend shows EMA above SMA, price near support without capitulation, no immediate catalysts, and historical patterns suggest recovery from similar pullbacks....
2025-08-11	HOLD LONG
Summary: Holding the long position as the overall uptrend persists with EMA above SMA, price near support levels, no immediate catalysts, and no volume capitulation to signal reversal....
2025-08-08	HOLD LONG
Summary: BSX maintains an overall uptrend with EMA above SMA despite the recent pullback below both, supported by strong Q2 2025 earnings beat, raised FY2025 guidance to EPS $2.95-2.99 and revenue growth of 18-19%, positive sentiment from analyst upgrades and institutional interest, with no immediate earnings or catalysts in the next 3 days, justifying holding the long position entered at $103.64 even as price dips to $103.5....
2025-08-07	HOLD LONG
Summary: BSX is experiencing a pullback below the EMAs but remains in an overall uptrend with EMA above SMA, supported by strong Q2 earnings beat, raised FY2025 guidance to EPS $2.95-2.99 and revenue ~$19.8B (up 18-19%), positive analyst upgrades like Oppenheimer's $118 PT, and institutional buying, with no immediate earnings or catalysts, justifying holding the long position from $103.64 despite the dip to $102.64....
2025-08-06	HOLD LONG
Summary: BSX remains in an uptrend with EMA above SMA, price dipping below on pullback but supported by strong Q2 earnings beat, raised FY2025 guidance to EPS $2.95-2.99 and revenue growth 18-19%, positive institutional activity like Vanguard increasing holdings, and no immediate catalysts or earnings within 3 days, justifying holding the long position from $103.64 despite the recent dip to $102.98....
2025-08-05	HOLD LONG
Summary: BSX continues in an uptrend with EMA above SMA, price slightly below EMA on the latest bar but above SMA, supported by strong Q2 earnings beat, raised FY2025 guidance, and no immediate negative catalysts or earnings within 3 days, justifying holding the long position from $103.64 despite the minor pullback....
2025-08-04	HOLD LONG
Summary: BSX maintains a strong uptrend with EMA above SMA and price above both, supported by recent Q2 earnings beat with 22.8% revenue growth and raised FY2025 guidance to $2.95-2.99 EPS and ~18-19% sales, justifying continued holding of the long position from $103.64 as no resistance is breached and momentum persists without negative catalysts....
2025-08-01	HOLD LONG
Summary: BSX remains in a clear uptrend with EMA above SMA and price above both, bolstered by today's raised FY 2025 guidance exceeding consensus and strong Q2 sales growth of 22.8%, justifying continued holding of the long position from $103.64 without immediate resistance breaches or negative catalysts....
2025-07-31	HOLD LONG
Summary: BSX maintains its uptrend with EMA above SMA and price above both, supported by strong Q2 earnings beat, raised guidance, and positive analyst upgrades, justifying holding the long position from $103.64 amid consolidation near recent highs without immediate exit signals....
2025-07-30	HOLD LONG
Summary: BSX continues its strong uptrend with EMA above SMA and price above both, bolstered by recent Q2 earnings beat, raised guidance, and analyst price target increases, holding the long position from $103.64 eight bars ago amid consolidation near 107 without catalysts for exit....
2025-07-29	HOLD LONG
Summary: BSX remains in a clear uptrend with EMA above SMA and price above both, supported by strong Q2 earnings beat and raised FY2025 guidance, consolidating near resistance at 107 with no immediate catalysts to exit the multi-week long position entered at 103.64 seven bars ago....
2025-07-28	HOLD LONG
Summary: BSX remains in a clear uptrend post strong Q2 earnings beat and raised FY25 guidance, with price above EMA/SMA, positive MACD, and consolidation above support after testing resistance at 107, supported by favorable analyst sentiment and no near-term catalysts to disrupt momentum....
2025-07-25	HOLD LONG
Summary: BSX remains in a clear uptrend with EMA above SMA and price above both, supported by strong Q2 2025 earnings beat and raised FY guidance, positive analyst upgrades, and recent price consolidation above key support at 103-104 after testing resistance near 107-108, justifying continued long hold for potential multi-week upside....
2025-07-24	HOLD LONG
Summary: BSX remains in a clear uptrend post strong Q2 earnings beat and raised FY2025 guidance, with price above EMA/SMA, positive MACD, and no trend invalidation, supporting continued multi-week hold from entry at $103.64....
2025-07-23	HOLD LONG
Summary: BSX reported strong Q2 2025 earnings today with beats on EPS and revenue, raised full-year guidance, and the stock gapped up on high volume, confirming the ongoing uptrend and supporting holding the long position entered 3 bars ago at $103.64 for a multi-week horizon....
2025-07-22	HOLD LONG
Summary: Hold long position as trend remains up with positive fundamentals and upcoming earnings expected to be favorable, despite short-term pullback....
2025-07-21	HOLD LONG
Summary: Continue holding long as uptrend persists with EMA above SMA and price above both, supported by strong fundamentals including recent acquisitions and positive earnings momentum, with no trend invalidation despite consolidation near 104 and upcoming Q2 earnings on July 24 expected to be favorable based on analyst upgrades....
2025-07-18	BUY
Summary: BSX is in a sustained uptrend with positive MACD, neutral RSI, and consolidation near key support after hitting resistance at 107, supported by strong fundamentals including recent acquisitions and positive earnings momentum, presenting a favorable risk/reward for a multi-week long hold....